Pfizer's Weak Q2 Sales Highlight Dependence On The Pipeline
Sales in almost all of Pfizer's key pharmaceutical businesses fell in the second quarter, sending the company's stock price down 4.5%.
Sales in almost all of Pfizer's key pharmaceutical businesses fell in the second quarter, sending the company's stock price down 4.5%.